Yoojeong Park

Yoojeong Park

Auto-generated profile, based on publicly available information

Yoojeong Park


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Gut and Liver
Verified
Journal Article
Open access
PDF file
MKMinwook Kim
Minwook Kim
YPYoojeong Park
Yoojeong Park
YKYou Sun Kim
You Sun Kim
SKSungjin Ko
Sungjin Ko
Minwook Kim, Yoojeong Park, You Sun Kim, Sungjin Ko. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl240005

31 October 2023 in Intestinal Research
Verified
Journal Article
Open access
PDF file
YKYou Sun Kim
You Sun Kim
EHEdward H. Hurley
Edward H. Hurley
YPYoojeong Park
Yoojeong Park
SKSungjin Ko
Sungjin Ko
Primary sclerosing cholangitis (PSC) is a progressive cholestatic, inflammatory, and fibrotic disease that is strongly associated with inflammatory bowel disease (IBD). PSC-IBD represents a unique disease entity and patients with this disease have an increased risk of malignancy development, such as colorectal cancer and cholangiocarcinoma. The pathogenesis of PSC-IBD involves genetic and environmental factors such as gut dysbiosis and bile acids alteration. However, despite the advancement of disease characteristics, no effective medical therapy has proven to have a significant impact on the prognosis of PSC. The treatment options for patients with PSC-IBD do not differ from those for patients with PSC alone. Potential candidate drugs have been developed based on the pathogenesis of PSC-IBD, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis. In this review, we summarize the current medical treatments for PSC-IBD and the status of new emerging therapeutic agents.

29 August 2024 in Cells
Verified
Journal Article
Open access
PDF file
YPYoojeong Park
Yoojeong Park
SHShikai Hu
Shikai Hu
MKMinwook Kim
Minwook Kim
Michael OertelMichael Oertel
Michael Oertel
ASAatur D. Singhi
Aatur D. Singhi
SKSungjin Ko
Sungjin Ko
Combined hepatocellular carcinoma–cholangiocarcinoma (cHCC-CCA) is a challenging primary liver cancer subtype with limited treatment options and a devastating prognosis. Recent studies have underscored the context-dependent roles of SOX9 in liver cancer formation in a preventive manner. Here, we revealed that liver-specific developmental Sox9 elimination using Alb-Cre;Sox9(flox/flox) (LKO) and CRISPR/Cas9-based tumor-specific acute Sox9 elimination (CKO) in SB-HDTVI-based Akt-YAP1 (AY) and Akt-NRAS (AN) cHCC-CCA models showed contrasting responses. LKO abrogates the AY CCA region while stimulating poorly differentiated HCC proliferation, whereas CKO prevents AY and AN cHCC-CCA development irrespective of tumor cell fate. Additionally, AN, but not AY, tumor formation partially depends on the Sox9-Dnmt1 cascade. SOX9 is dispensable for AY-mediated, HC-derived, LPC-like immature CCA formation but is required for their maintenance and transformation into mature CCA. Therapeutic Sox9 elimination using the OPN-CreERT2 strain combined with inducible Sox9 iKO specifically reduces AY but not AN cHCC-CCA tumors. This necessitates the careful consideration of genetic liver cancer studies using developmental Cre and somatic mutants, particularly for genes involved in liver development. Our findings suggest that SOX9 elimination may hold promise as a therapeutic approach for a subset of cHCC-CCA and highlight the need for further investigation to translate these preclinical insights into personalized clinical applications.

1 September 2025 in Cancer Research Communications
Verified
Journal Article
Open access
MKMinwook Kim
Minwook Kim
YPYoojeong Park
Yoojeong Park
RCRachel Covitz
Rachel Covitz
JKJoseph Kwon
Joseph Kwon
JLJia-Jun Liu
Jia-Jun Liu
SKSungjin Ko
Sungjin Ko
Hepatocytes (HC), which share a developmental origin with cholangiocytes (CC), have the capacity to undergo reparative reprogramming into CCs in response to liver injury and, under specific conditions, can also transform malignantly into cholangiocarcinoma (CCA). However, the molecular mechanisms governing HC plasticity in liver diseases remain poorly understood. In this study, we investigated the role of spalt-like transcription factor 4 (SALL4), an oncofetal transcription factor, in both malignant and regenerative HC fate transitions toward the biliary lineage. Using Sleeping Beauty hydrodynamic tail vein injection–mediated murine liver cancer models, we explored HC-to-CCA transformation, whereas the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet–induced cholestasis model was used to investigate regenerative HC-to-CC reprogramming. Our findings reveal that SALL4 is specifically required for myristoylated Akt–YAP1S127A-driven HC-to-CCA transformation, as its loss significantly suppressed malignant reprogramming and clonal expansion. Surprisingly, Sall4 overexpression also prevented YAP1S127A-driven CCA development while promoting the expansion of liver progenitor cell (LPC)-like fatty HCs. Mechanistically, we propose Bmi1 as a key downstream effector of SALL4 in YAP1-dependent HC-to-CCA transformation. Additionally, in the DDC–fed cholestasis model, Sall4 deletion enhanced HC-to-LPC activation while impairing LPC differentiation into mature CCs. These findings establish SALL4 as a critical regulator of HC plasticity in both malignant and regednerative contexts and highlight its potential as a therapeutic target for specific liver cancer subtypes. Significance: HC plasticity supports repair but can drive malignancy, acting as a double-edged sword. We identify SALL4 as regulator of YAP1-driven HC-to-CC reprogramming, revealing the YAP1–SALL4–BMI1 axis as a therapeutic target for CCA.

25 September 2025
Verified
Other
Open access
MKMinwook Kim
Minwook Kim
YPYoojeong Park
Yoojeong Park
RCRachel Covitz
Rachel Covitz
JKJoseph Kwon
Joseph Kwon
JLJia-Jun Liu
Jia-Jun Liu
SKSungjin Ko
Sungjin Ko
SALL4 regulates regenerative HC-to-CC conversion in the DDC-fed cholestasis model. A, Schematic experimental design. Sall4fl/fl mice were injected with either AAV8-TBG-GFP (Sall4 WThep-GFP) or AAV8-TBG-Cre (Sall4 KOhepΔGFP) 2 weeks prior administration of a DDC-containing diet for 4 weeks. Liver tissues were analyzed at the end of the treatment period. B, LW/BW ratio comparison and serum biochemistry analysis comparing alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin levels between Sall4 WThep-GFP and Sall4 KOhepΔGFP groups (n = 4–6 mice per group). C, Representative images of CD45 IHC and Sirius Red staining in livers sections from both groups. D and E, Quantification of (D) CD45+ inflammatory cells per 1,000 μm2 and (E) collagen deposition (%) by Sirius Red staining. F, Representative liver sections stained with hematoxylin and eosin (H&E), SOX9 (CC lineage marker), and Ki-67 (proliferation marker). G and H, Quantification of (G) SOX9+ cells (%) and (H) Ki-67+ cells in the periportal area (%). I, IF staining for SOX9, HNF4A, and GFP. Yellow arrowheads indicate intermediate cells expressing both CC (SOX9) and HC (HNF4A) markers. J, Quantification of SOX9+HNF4A+ double-positive intermediate cells among total HNF4A+ cells (%). K, IF staining for CK19 and GFP to visualize HC-derived CC. L, Quantification of CK19+ CCs per microscopic field. M, Quantification of CK19+GFP+ double-positive cells among total CK19+ cells (%). Data are presented as the mean ± SD; Student t test (*, P < 0.05; **, P < 0.01; ****, P < 0.0001; ns, not significant). Scale bars, (C–F) 100 μm; (K–M) 50 μm.

25 September 2025
Verified
Other
Open access
MKMinwook Kim
Minwook Kim
YPYoojeong Park
Yoojeong Park
RCRachel Covitz
Rachel Covitz
JKJoseph Kwon
Joseph Kwon
JLJia-Jun Liu
Jia-Jun Liu
SKSungjin Ko
Sungjin Ko
Primers and plasmids for the cloning Plasmids